Demand for Taenia solium Cysticercosis Vaccine: Lessons and Insights From the Pig Production and Trading Nodes of the Uganda Pig Value Chain

Taenia solium cysticercosis disease remains a key challenge to the pig sector in low- and middle-income countries in sub-Saharan Africa, Latin America and South East Asia, resulting in both economic losses and public health impacts. The World Health Organization has ranked it first on the global scale of foodborne parasites. A One Health approach has been recommended for reduction of infection pressure and eradication in the longer term. A new vaccine TSOL18 (Cysvax™), applied in combination with oxfendazole (Paranthic 10%™), a dewormer drug has been developed and field tested for the control of T. solium cysticercosis, with high potential to break the disease cycle. It is however unclear whether the products can be marketed through a market driven approach, and if smallholder pig farmers would be willing to take up and pay for the vaccine–oxfendazole combination. A choice experiment methodology was used to assess the potential demand and willingness to pay for the vaccine—oxfendazole combination by Ugandan smallholder pig farmers, and demand for vaccinated pigs by pig traders. The results showed that farmers highly valued quality assurance attributes and were not keen on the vaccine if there were no associated returns in the form of premium price for vaccinated pigs during sales. They were willing to pay US$ 2.31 for the vaccine if it resulted in a premium price for vaccinated pigs. Furthermore, they preferred an accompanying vaccine viability detector as part of its quality assurance. The pig traders on the other hand preferred high carcass weight of pigs, potentially achieved by using oxfendazole. The results show that unless the pig market systems pay a premium price for vaccinated pigs, and quality assurance systems guarantee quality vaccine, uptake of the TSOL18 vaccine and oxfendazole by farmers through market mechanisms may be unsuccessful. The current pig marketing system does not reward food safety, the focus is mainly on carcass weight. Alternative delivery mechanisms for the vaccine through a mix of private–public investments needs to be explored, as the benefits of vaccinated pigs are societal and include reduction and elimination of neurocysticercosis in the long run.

African swine fever control and market integration in Ugandan peri-urban smallholder pig value chains: An ex-ante impact assessment of interventions and their interaction

Pig production in peri-urban smallholder value chains in Uganda is severely constrained by impact of disease, particularly African swine fever (ASF), and the economic consequences of an inefficient pig value chain. Interventions in the form of biosecurity to control ASF disease outbreaks and pig business hub models to better link smallholder farmers to pig markets have the potential to address the constraints. However, there is a dearth of evidence of the effects of the interventions on performance and distribution of outcomes along the pig value chain. An ex-ante impact assessment utilising System Dynamics model was used to assess the impact of the interventions in peri-urban pig value chains in Masaka district. The results showed that although implementation of biosecurity interventions results in reduction of ASF outbreaks, it also leads to a 6.3% reduction in farmer profit margins per year but more than 7% increase in other value chain actors' margins. The pig business hub intervention alone results in positive margins for all value chain actors but minimal reduction in ASF outbreaks. When biosecurity and the pig business hub interventions are implemented together, the interaction effects of the interventions result in positive outcomes for both the control of ASF and improvement in farmers' margins. Farmers may therefore be unwilling to adopt biosecurity practices if implemented alone to control ASF outbreaks unless there is a corresponding financial incentive to compensate for the high costs. This has implications for policy or developing institutions to facilitate cost sharing arrangement among chain actors and/or third party subsidy to provide incentives for producers to adopt biosecurity measures.